8-(4-chloro-2,6-dimethylphenylamino)-4-methyl-2H-phthalazin-1-one | 1072157-25-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 8-(4-chloro-2,6-dimethylphenylamino)-4-methyl-2H-phthalazin-1-one
• 英文别名: 8-(4-chloro-2,6-dimethylanilino)-4-methyl-2H-phthalazin-1-one
• CAS: 1072157-25-5
• 化学式: C₁₇H₁₆ClN₃O
• 分子量: 313.787
• InChiKey: DYKCXRTWIYHDTB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  53.5
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• S1PR2 ANTAGONISTS AND USES THEREFOR
  申请人：Dalhousie University

  公开号：EP3298014A1

  公开（公告）日：2018-03-28
• [EN] BLOCKERS OF THE NOGO-A S1PR PATHWAY FOR THE TREATMENT OF DISEASES CHARACTERIZED BY NEURONAL DAMAGE AND LACK OF SUBSEQUENT REPAIR<br/>[FR] BLOQUEURS DE LA VOIX NOGO-A S1PR POUR LE TRAITEMENT DE MALADIES CARACTÉRISÉES PAR UNE LÉSION NEURONALE ET UN DÉFAUT DE RÉPARATION ULTÉRIEURE
  申请人：UNIV ZUERICH

  公开号：WO2012164103A2

  公开（公告）日：2012-12-06

  The present invention provides inhibitors capable of binding to a member of the S1PR receptor group comprised of S1PR2 and S1PR5 with a dissociation constant of 5x10-7 mol/l or smaller for treating neuronal damage, specifically an antibody, an antibody fragment, an antibody-like molecule, a nucleic acid aptamer or an oligopeptide with 6 to 30 amino acid residues in length. Similarly, an interfering RNA or an antisense modulator of gene expression of G13 or a member of the S1PR receptor group described above are provided for treating of neuronal damage.
• [EN] S1PR2 ANTAGONISTS AND USES THEREFOR<br/>[FR] ANTAGONISTES DE S1PR2 ET LEURS UTILISATIONS
  申请人：UNIV DALHOUSIE

  公开号：WO2016191872A1

  公开（公告）日：2016-12-08

  Methods and compositions are provided for the treatment of familial exudative vitreoretinopathy (FEVR) through the administration of a therapeutically effective amount of a sphingosine-1-phosphate receptor type 2 (S1PR2) antagonist. Also provided herein are compounds which contain bioisosteric replacements of the urea group of JTE- 013 and analogs thereof, and their use in treating retinopathies and diseases characterized by insufficient angiogenesis.